Omeros (OMER) PEG Ratio: History & Chart

Omeros Corporation(OMER)

Biotechnology · Seattle, WA

$18.58-0.32 (-1.69%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Omeros Corporation

Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.

Seattle, WA

175 employees

www.omeros.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Gregory A. Demopulos

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Omeros Corporation (OMER)	$1.34B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.33B	N/A	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.31B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.39B	N/A	N/A	N/A	N/A
Taysha Gene Therapies, Inc. (TSHA)vs ›	$1.40B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.41B	N/A	N/A	N/A	N/A
The Pennant Group, Inc. (PNTG)vs ›	$1.41B	4.48	2.78	1.98	1.98
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	N/A	N/A	N/A	N/A
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.43B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.43B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Omeros Corporation (OMER)

$1.34B

N/A

Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›

$1.33B

N/A

Alpha Tau Medical Ltd (DRTS)vs ›

$1.31B

N/A

Inhibrx Biosciences Inc. (INBX)vs ›

$1.39B

N/A

Taysha Gene Therapies, Inc. (TSHA)vs ›

$1.40B

N/A

Kailera Therapeutics, Inc. (KLRA)vs ›

$1.41B

N/A

The Pennant Group, Inc. (PNTG)vs ›

$1.41B

4.48

2.78

1.98

AnaptysBio, Inc. (ANAB)vs ›

$1.42B

N/A

Ultragenyx Pharmaceutical Inc. (RARE)vs ›

$1.43B

N/A

Maze Therapeutics, Inc. (MAZE)vs ›

$1.43B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

OMER PEG Ratio Metrics

OMER Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics